- Home
- BFAC vs CGEN Comparison
BFAC vs CGEN Comparison
Compare BFAC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFAC
- CGEN
- Stock Information
- Founded
- BFAC 2021
- CGEN 1993
- Country
- BFAC United States
- CGEN Israel
- Employees
- BFAC N/A
- CGEN N/A
- Industry
- BFAC Blank Checks
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BFAC Finance
- CGEN Health Care
- Exchange
- BFAC Nasdaq
- CGEN Nasdaq
- Market Cap
- BFAC 152.7M
- CGEN 142.8M
- IPO Year
- BFAC 2021
- CGEN 2000
- Fundamental
- Price
- BFAC $11.14
- CGEN $1.59
- Analyst Decision
- BFAC
- CGEN Strong Buy
- Analyst Count
- BFAC 0
- CGEN 2
- Target Price
- BFAC N/A
- CGEN $4.00
- AVG Volume (30 Days)
- BFAC 4.3K
- CGEN 445.1K
- Earning Date
- BFAC 01-01-0001
- CGEN 11-12-2024
- Dividend Yield
- BFAC N/A
- CGEN N/A
- EPS Growth
- BFAC 49.83
- CGEN N/A
- EPS
- BFAC 0.37
- CGEN 0.02
- Revenue
- BFAC N/A
- CGEN $59,852,000.00
- Revenue This Year
- BFAC N/A
- CGEN $57.27
- Revenue Next Year
- BFAC N/A
- CGEN N/A
- P/E Ratio
- BFAC $29.86
- CGEN $88.75
- Revenue Growth
- BFAC N/A
- CGEN 698.03
- 52 Week Low
- BFAC $10.84
- CGEN $1.35
- 52 Week High
- BFAC $11.55
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- BFAC 67.74
- CGEN 51.01
- Support Level
- BFAC $11.11
- CGEN $1.55
- Resistance Level
- BFAC $11.14
- CGEN $1.68
- Average True Range (ATR)
- BFAC 0.00
- CGEN 0.08
- MACD
- BFAC 0.00
- CGEN 0.01
- Stochastic Oscillator
- BFAC 100.00
- CGEN 52.17
About BFAC Battery Future Acquisition Corp.
Battery Future Acquisition Corp is a blank check company.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.